Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study

Tursi, Antonio; Elisei, Walter; Picchio, Marcello; Zampaletta, Costantino; Pelecca, Giorgio; Faggiani, Roberto; Brandimarte, Giovanni

doi:10.1007/s10151-014-1177-1

Cited by 34 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been one study comparing infliximab and adalimumab, but this included a highly selected patient group, and was excluded from our metaanalysis. 43 In this RCT, both intervention groups were given a short, 2-week course of metronidazole, and participants were selected to be those at high risk of recurrence with the presence of two known risk factors for CD recurrence. There was no significant difference in rates of endoscopic recurrence at 12 months (p = 0.10) with 3 out 20 patients overall receiving either drug reaching this endpoint.…”

Section: Pooled Adverse Eventsmentioning

confidence: 99%

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease

Burr

Hall

Hamlin

et al. 2018

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

Section: Pooled Adverse Eventsmentioning

confidence: 99%

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease

Burr

Hall

Hamlin

et al. 2018

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

“…The objective of this study was to compare the efficacy of therapies for preventing CD recurrence after surgery, including mesalazine [2–8], budesonide [9, 10], azathioprine [4, 8, 11], ornidazole [12], infliximab [6, 13, 14], adalimumab [8, 14], Tripterygium wilfordii Hook. f. [5, 11], Lactobacillus GG [15], and untreated intervention [7], alone or combination therapies preventing CD recurrence after surgery, based on direct and indirect evidence from RCTs.…”

Section: Introductionmentioning

confidence: 99%

Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis

Feng

Chen

et al. 2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objective To assess the benefits of different treatments that aim to prevent the endoscopic recurrence of Crohn's disease (CD) after ileal resection. Methods Randomized controlled trials (RCTs) were searched from MEDLINE, Embase, and the Cochrane Central Database. All the included RCTs with an endoscopic recurrence outcome which was defined as Rutgeerts' score ≥ i2 have a duration of more than 1 year. The quality of the included RCTs was assessed by the Cochrane Risk of Bias Tool. Pairwise treatment effects were estimated through a Bayesian random effects network meta-analysis by using the OpenBUGS 1.4 software and reported as odds ratios (ORs) with a 95% credible interval (CI). Results Fourteen RCTs (877 participants) were included. Two strategies were superior to placebo for preventing endoscopic recurrence of CD at 1 year after surgery: infliximab (d, −5.475; 95% CI, −10.47 to –1.632) and adalimumab (d, −7.273; 95% CI, −13.84 to −2.585). Nine strategies were not effective: budesnoid, mesalazine (in both high and low dose), azathioprine, Tripterygium wilfordii, mesalazine + infliximab, ornidazole, untreated intervention, and Lactobacillus GG. Conclusions Except for infliximab and adalimumab, other strategies included in our analysis were not effective for preventing endoscopic recurrence of CD at 1 year after ileal resection.

show abstract

“…At the end of the follow-up there was no significant difference in clinical recurrence between adalimumab and infliximab (1 patient from the two groups developed symptoms), with a slight predominance of endoscopic recurrence in the IFX group (2 patients compared with 1 in the ADA group) (19). They stated in this study that surgery is often required in CD patients, but it may be not be curative and considering the high probability of POR, preventative therapy may be recommended, especially in a group of patients who present risk factors considered in their study such as active smoking, penetrating disease and previous surgery (19).…”

Section: Discussionmentioning

confidence: 99%

“…(19) In Crohn's disease, for patients at high risk of post-operative recurrence, adalimumab is superior to thiopurines in preventing early disease recurrence (20).…”

Section: Introductionmentioning

confidence: 99%

Adalimumab versus Infliximab in treating post-operative recurrence of Crohns disease: a national cohort study

et al. 2016

View full text Add to dashboard Cite

Aim: Perform a comparison between adalimumab (ADA) and infliximab (IFX) in treating post-operative recurrence of Crohn's disease (a comparative analysis of efficacy and safety).Methods: From the 267 patients treated with adalimumab or infliximab between January 2005 and June 2014 in Romania, 44 received anti-TNF (tumor necrosis factor) therapy for prevention of post-operative recurrence. A comparison between patients treated with IFX and ADA was made with the Chi-square and t-student test, with the aid of the statistical program Mini Tab 17.Results: Twenty-one patients received IFX and 23 ADA. This included 49% males (22/44), with a mean age of 41 years, mean disease duration of 6 years, and 84.1% had previously received azathioprine. The IFX group is comparable with the ADA group regarding most of the parameters, except for therapy duration. Mean duration of therapy was 33 months. The rate of complete response was comparable between the two groups: 67% in the IFX group vs. 78.3% in the ADA group, the same as the rate of reresection, 19.1% vs. 4.4% and the rate of endoscopic recurrence, 29 vs. 33% at 12 months. Risk factors for postoperative recurrence (POR) (male sex, younger age, ileocolonic location, stricturing or penetrating behaviour) were studied, only ileocolonic location was found to be associated with Crohn's disease recurrence in patients treated with ADA.Conclusions: Overall infliximab and aalimumab are equally efficient in patients with resected Crohn's disease (CD) with a complete response of 72.7%, a rate of re-resection of 11.4% and a rate of endoscopic recurrence of 35%. Ileocolonic location might be a predictive factor for loss of response to adalimumab in resected Crohn's disease patients.

show abstract

Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study

Abstract: IFX and ADA were similar in preventing histological, endoscopic and clinical recurrence after curative ileocolonic resection in high risk CD patients.

Cited by 34 publications

References 35 publications

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease

Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis

Adalimumab versus Infliximab in treating post-operative recurrence of Crohns disease: a national cohort study

Contact Info

Product

Resources

About

Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study

Abstract: IFX and ADA were similar in preventing histological, endoscopic and clinical recurrence after curative ileocolonic resection in high risk CD patients.

Cited by 34 publications

References 35 publications

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease

Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis

Adalimumab versus Infliximab in treating post-operative recurrence of Crohns disease: a national cohort study

Contact Info

Product

Resources

About

Adalimumab versus Infliximab in treating post-operative recurrence of Crohns disease: a national cohort study